1092070-97-7 = 832720-36-2 反应条件:1.1 Reagents: Lithium Hydroxide Solvents: Methanol,Water; 16 H,45 °C2.1 Reagents: Sodium Hydroxide Solvents: Tetrahydrofuran,Water; Overnight,50 °C2.2 Reagents: Citric Acid Solvents: Water; Ph 3 标题:Discovery Of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-Methoxyphenyl)-3-(2-Fluoro-6-[trifluoromethyl]Benzyl)-4-Methyl-2,6-Dioxo-3,6-Dihydro-2H-Pyrimidin-1-Yl]-1-Phenylethylamino}Butyrate (Elagolix),A Potent And Orally Available Nonpeptide Antagonist Of The Human Gonadotropin-Releasing Hormone Receptor 作者:Chen,Chen; Et Al 参考文献:Journal Of Medicinal Chemistry 日期:2008 卷标:51(23) 页码:7478-7485]
832720-84-0 = 832720-36-2 反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Ethanol,Water 标题:Elagolix Sodium Salt And Its Synthetic Intermediates: A Spectroscopic,Crystallographic,And Conformational Study 作者:Ciceri,Samuele; Et Al 参考文献:Molecules 日期:2023 卷标:28(9)]
834153-87-6 = 832720-36-2 反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Tetrahydrofuran,Water; Overnight,50 °C1.2 Reagents: Citric Acid Solvents: Water; Ph 3 标题:Discovery Of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-Methoxyphenyl)-3-(2-Fluoro-6-[trifluoromethyl]Benzyl)-4-Methyl-2,6-Dioxo-3,6-Dihydro-2H-Pyrimidin-1-Yl]-1-Phenylethylamino}Butyrate (Elagolix),A Potent And Orally Available Nonpeptide Antagonist Of The Human Gonadotropin-Releasing Hormone Receptor 作者:Chen,Chen; Et Al 参考文献:Journal Of Medicinal Chemistry 日期:2008 卷标:51(23) 页码:7478-7485
恶拉戈利 反应生成 恶拉戈利钠 参考文献: Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists[fr] Derives De Pyrimidine-2,4-Dione Utilises Comme Antagonistes Du Recepteur D'Hormone Liberant De La Gonadotrophine 标题: Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists[fr] Derives De Pyrimidine-2,4-Dione Utilises Comme Antagonistes Du Recepteur D'Hormone Liberant De La Gonadotrophine 摘要:Gnrh受体拮抗剂被披露,对男性和女性的各种与性激素相关的疾病具有治疗作用.本发明的化合物具有以下结构:其中r1A,R1B,R1C,R2A,R2B,R3,R4,R5,R6和x的定义如本文所述,包括立体异构体,前药和其药用可接受盐.还披露了含有本发明化合物的组合物与药用可接受载体的组合物,以及与在需要时对抗性腺激素释放激素的使用方法.
专利号:US-11858901-B2 优先权日:2019-10-30 标 题:3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix 发明人:BALLETTE ROBERTO; JIMÉNEZ ALONSO OSCAR; GARCÃ?A GARCÃ?A ELENA; DOBARRO RODRÃ?GUEZ ALICIA 权利人:MOEHS IBERICA SL 摘要:A new intermediate is useful in the synthesis of elagolix. A process for obtaining the intermediate includes reacting a precursor with iodine monochloride in the presence of an organic solvent. A process for preparing elagolix makes use of the intermediate. The intermediate can be 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6-trifluoromethylbenzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, such as a hydrochloride.
专利号:US-11840519-B2 优先权日:2019-09-03 标 题 :Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process 发明人:LENNA ROBERTO; FASANA ANDREA; ORTIZ JERRY 权利人:IND CHIMICA SRL 摘要:The present invention to a process for the preparation of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-amino]-butanoic acid, compound also known as Elagolix sodium salt, having the formula (I) reported below:
专利号:US-2022281829-A1 优先权日:2019-09-03 标题 :Process for the synthesis of the sodium salt of 4-[[(1r)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2,6- dioxo-1(2h)-pyrimidinyl]-1- phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process
专利号:ES-2802815-A1 优先权日:2019-07-12 标 题:SALT 3- [2 (R) -AMINO-2-PHENYLETHYL] -5- (2-FLUORO-3-METOXIFENIL) -1- [2-FLUORO-6- (TRIFLUOROMETIL) BENZYL] -6-METHYL-1H -PYRIMIDIN-2,4 (1H, 3H) -DIONA (I) IN SOLID FORM, PROCEDURE FOR ITS PREPARATION AND USE OF THE SAME IN THE SYNTHESIS OF ELAGOLIX
专利号:CA-3149179-A1 优先权日:2019-09-03 标题:Process for the synthesis of the sodium salt of 4-[[(1r)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2h)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process
专利号:US-2022411382-A1 优先权日:2019-10-30 标 题 :3-((r)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1h-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix
1: Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, Noertersheuser P, Gibbs MA, Mostafa NM. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clin Pharmacokinet. 2019 Nov 21. doi: 10.1007/s40262-019-00840-7. [Epub ahead of print] Review. doi: 10.2147/IJWH.S185023. eCollection 2019. Review. 3: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548061/ pii: F1000 Faculty Rev-529. doi: 10.12688/f1000research.14817.1. eCollection 2019. Review. 5: Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019 Apr;55(4):237-246. doi: 10.1358/dot.2019.55.4.2930713. Review. doi: 10.2147/TCRM.S147318. eCollection 2019. Review.
合成参考文献
参考文献:10.1007/s43032-022-00877-3 摘要:Leyland N, Leonardi M, Murji A, Singh SS, Al-Hendy A, Bradley L. A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids. Reproductive Sciences. 2022 Feb 17;29(4):1188–96. doi: 10.1007/s43032-022-00877-3.